Our pipeline: Creating innovative dermatological medicines

The unmet needs in dermatology demand differentiated thinking

  Preclinical Phase 2 Phase 3 NDA Filed
(4% minocycline foam)
for Moderate-to-Severe Acne        
(1.5% minocycline foam)
for Papulopustular Moderate-to-Severe Rosacea        
(3% minocycline + 0.3% adapalene foam)
for Moderate-to-Severe Acne        

The safety and efficacy of these investigational products have not been established. There is no guarantee that these products will receive health authority approval or become commercially available.

Dermatology has been dominated by a few big players who offer a range of similar products. Foamix sees a need for new thinking focused on enhancing the standard of care for the most common skin conditions.

Foamix is initially targeting acne and rosacea, conditions that affect a large number of patients. Today’s treatments for moderate-to-severe acne have some drawbacks. Topical antibiotics are generally preferred to oral therapies because they have less systemic absorption.

pipeline image
Pipeline image

The patients who live with these difficult conditions – and the physicians who treat them – deserve advances in treatment. Foamix is developing new treatments for these conditions, which, if approved, will provide patients and their physicians with new options.

We currently are investigating what could be, if approved, the world’s first topical minocycline-based therapies. They are:

  • FMX101, to treat inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older
  • FMX103, to treat moderate-to-severe papulopustular rosacea in adults

We are also developing FCD105, potentially the world’s first topical combination therapy of minocycline and adapalene for moderate-to-severe acne.